Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| China-Japan Friendship Hospital | OTHER |
| The Affiliated Hospital of Qingdao University | OTHER |
| Qianfoshan Hospital | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this observational multicenter retrospective cohort study is to evaluate the differences in risk factors, prognosis, clinicopathological and metabolic characteristics between early-onset pancreatic neuroendocrine tumors (EO-PanNETs) and late-onset pancreatic neuroendocrine tumors (LO-PanNETs).
The main questions it aims to answer are:
Are there distinct clinical, pathological, and metabolic profiles in EO-PanNETs compared with LO-PanNETs? Do EO-PanNETs have different prognostic outcomes compared with LO-PanNETs? Researchers will compare EO-PanNET patients with LO-PanNET patients and with matched nonmalignant controls to assess differences in tumor characteristics and associated metabolic conditions.
Participants will:
Provide retrospective clinical, pathological, and metabolic data from hospital records.
Have survival and recurrence outcomes assessed through follow-up data review.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Early-onset pancreatic neuroendocrine tumors group | This group comprises patients diagnosed with pancreatic neuroendocrine tumors before the age of 50 years. All cases were histopathologically confirmed and treated at one of the participating centers. | ||
| Late-onset pancreatic neuroendocrine tumors group | This group comprises patients diagnosed with pancreatic neuroendocrine tumors at or after the age of 50 years. All cases were histopathologically confirmed and treated at one of the participating centers. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Overall Survival | From date of randomization until the date of death from any cause or the date of the last follow-up, whichever came first, assessed up to 12 years |
| Measure | Description | Time Frame |
|---|---|---|
| Disease-specific survival | From date of diagnosis until death due to PanNETs, up to 12 years | |
| Progression-free survival | From date of diagnosis until the date of disease recurrence or death from any cause, whichever came first, assessed up to 12 years. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
The study population comprised adult patients (≥18 years) diagnosed with pancreatic neuroendocrine tumors (PanNETs) between 2013 and 2024. All cases had a histopathologically confirmed diagnosis and received treatment at one of the participating centers. Patients were excluded if they had poorly differentiated neuroendocrine carcinoma, mixed neuroendocrine-non-neuroendocrine neoplasm, undefined tumor differentiation, recurrent disease, non-initial treatment, or a history of other malignancies.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Hanxiang Zhan, MD. PhD. | Contact | +86 18560085156 | zhanhanxiang@hotmail.com | |
| Changhao Gao, MMed | Contact | gaochanghao44@gmail.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Qilu Hospital of Shandong University | Jinan | Shandong | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Disease-free survival | From date of surgery until first documented recurrence, metastasis, or death from any cause, assessed up to 12 years. |